3P Biopharmaceuticals appoints Kenneth McMahon as Head of Quality Control
Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments.
3P Biopharmaceuticals (3P), a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) appoints a new member as head of quality control.
Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments. He joined 3P with the objective of controlling and ensuring the correct quality of the manufactured products as well as compliance with the approved safety criteria.
He began his professional career in quality control at Genzyme (now Sanofi). In 2015 he joined the quality department at Bristol Myers Squibbs and since then he has continued to develop his knowledge and skills in the field of pharmaceutical quality.
After that, he worked for 4 years in positions of responsibility within the Quality Assurance and Quality Control departments at Samsung Biologics.
His professional career has been developed in GMP environments, and he is an expert in the design, development, and implementation of pharmaceutical quality systems, as well as in the management and quality control of pharmaceutical products.
“Joining a company like 3P is a fantastic opportunity to further develop my career and to be able to move back to Europe. I look forward to contributing successfully to their quality strategy”. Kenneth said on his arrival at the Noáin-based company.
Dámaso Molero, CEO of 3P Biopharmaceuticals said: “As an international company, we are excited to welcome Kenneth to our team. His extensive experience in senior quality positions will undoubtedly help us to strengthen the area to continue providing a high level of service”.
Therefore, with this new addition to the quality department, 3P continues its growth plan and consolidates its competitive position as one of the leading CDMOs in Europe.
View the full press release here
